Ophthalmic Evidence Engine™
We are committed to ensuring new therapies transition from research to clinical application.
Schedule a Demo
Diabetic Retinopathy
Dry AMD
Highlights
Data
Ophthalmic Evidence Engine™
We are committed to ensuring new therapies transition from research to clinical application.
Schedule a Demo
Diabetic Retinopathy
Dry AMD
Highlights
Data
Ophthalmic Evidence Engine™
We are committed to ensuring new therapies transition from research to clinical application.
Schedule a Demo
Diabetic Retinopathy
Dry AMD
Highlights
Data
Ophthalmic Evidence Engine™
We are committed to ensuring new therapies transition from research to clinical application.
Schedule a Demo
Diabetic Retinopathy
Dry AMD
Highlights
Data
Who we work with
Providers
We work with diverse categories of providers in and out of the network.
Life Sciences
Our platform is a solid option for science labs and crucial for diseases.
Payers
With our system, the payer saves on unnecessary costs and overheads.
Who we work with
Providers
We work with diverse categories of providers in and out of the network.
Life Sciences
Our platform is a solid option for science labs and crucial for diseases.
Payers
With our system, the payer saves on unnecessary costs and overheads.
Who we work with
Providers
We work with diverse categories of providers in and out of the network.
Life Sciences
Our platform is a solid option for science labs and crucial for diseases.
Payers
With our system, the payer saves on unnecessary costs and overheads.
Insight into retinal decease
Your data can be unlocked to illuminate new insights and illuminate a path to better patient care
Highlighted
Highlighted
Highlighted
Insight into retinal decease
Your data can be unlocked to illuminate new insights and illuminate a path to better patient care
Highlighted
Highlighted
Highlighted
Insight into retinal decease
Your data can be unlocked to illuminate new insights and illuminate a path to better patient care
Highlighted
Highlighted
Highlighted
Ophthalmology provider solutions
Amaros offers curation and analytics solutions to help eye care centers make sense of incomplete EHR data. Our Real World Evidence solution helps researchers gain insight into patient populations and disease outcomes to bring new insights into eye care.
Image-Based Biomarker
Unlock the potential of your clinical data through our expert technology-enabled, disease specific, longitudinal patient record curation.
Highly Intuitive Analytics
Administrators gain direct access to clinically relevant metrics and reporting, eliminating the need for onsitetechnology support.
Compare Cohorts
View clinically similar patient cohorts side-by-side to understand differences in care and outcomes.
Analyze Outcomes
Understand real world outcomes within your patient population.
Identify Treatment Patterns
Gain insight into variations in care delivery. Understand the consistency of care among your physicians and across locations.
Track Key Metrics
Track widely accepted oncology care standards with the option to create custom metrics for your institution.
Ophthalmology provider solutions
Amaros offers curation and analytics solutions to help eye care centers make sense of incomplete EHR data. Our Real World Evidence solution helps researchers gain insight into patient populations and disease outcomes to bring new insights into eye care.
Image-Based Biomarker
Unlock the potential of your clinical data through our expert technology-enabled, disease specific, longitudinal patient record curation.
Highly Intuitive Analytics
Administrators gain direct access to clinically relevant metrics and reporting, eliminating the need for onsitetechnology support.
Compare Cohorts
View clinically similar patient cohorts side-by-side to understand differences in care and outcomes.
Analyze Outcomes
Understand real world outcomes within your patient population.
Identify Treatment Patterns
Gain insight into variations in care delivery. Understand the consistency of care among your physicians and across locations.
Track Key Metrics
Track widely accepted oncology care standards with the option to create custom metrics for your institution.
Ophthalmology provider solutions
Amaros offers curation and analytics solutions to help eye care centers make sense of incomplete EHR data. Our Real World Evidence solution helps researchers gain insight into patient populations and disease outcomes to bring new insights into eye care.
Image-Based Biomarker
Unlock the potential of your clinical data through our expert technology-enabled, disease specific, longitudinal patient record curation.
Highly Intuitive Analytics
Administrators gain direct access to clinically relevant metrics and reporting, eliminating the need for onsitetechnology support.
Compare Cohorts
View clinically similar patient cohorts side-by-side to understand differences in care and outcomes.
Analyze Outcomes
Understand real world outcomes within your patient population.
Identify Treatment Patterns
Gain insight into variations in care delivery. Understand the consistency of care among your physicians and across locations.
Track Key Metrics
Track widely accepted oncology care standards with the option to create custom metrics for your institution.
Advance with Insight
When you're focusing on the future of retina care, it helps to start with a clear and accurate picture of the present
Stay up to date
Get notified about Amaros softwere
Advance with Insight
When you're focusing on the future of retina care, it helps to start with a clear and accurate picture of the present
Stay up to date
Get notified about Amaros softwere
Advance with Insight
When you're focusing on the future of retina care, it helps to start with a clear and accurate picture of the present
Stay up to date
Get notified about Amaros softwere
Advance with Insight
When you're focusing on the future of retina care, it helps to start with a clear and accurate picture of the present
Stay up to date
Get notified about Amaros softwere
Data Highlights
Amaros leverages our proprietary amalgam neural network and ophthalmology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
GA patient database
• Number of patients 16,000+
• Mean clinic visits 35+
• Mean image visits 15
Biomarker Identification & Monitoring
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
Data Highlights
Amaros leverages our proprietary amalgam neural network and ophthalmology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
GA patient database
• Number of patients 16,000+
• Mean clinic visits 35+
• Mean image visits 15
Biomarker Identification & Monitoring
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
Data Highlights
Amaros leverages our proprietary amalgam neural network and ophthalmology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
GA patient database
• Number of patients 16,000+
• Mean clinic visits 35+
• Mean image visits 15
Biomarker Identification & Monitoring
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
Data Highlights
Amaros leverages our proprietary amalgam neural network and ophthalmology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
GA patient database
• Number of patients 16,000+
• Mean clinic visits 35+
• Mean image visits 15
Biomarker Identification & Monitoring
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
The backbone for ophthalmology
API requests per day, 1,200 requests a minute.
Amaros system uptime and running AI models
Retina clinics in the network market share
Pharma Data bases and 6 Languages supported
The backbone for ophthalmology
API requests per day, 1,200 requests a minute.
Amaros system uptime and running AI models
Retina clinics in the network market share
Pharma Data bases and 6 Languages supported
The backbone for ophthalmology
API requests per day, 1,200 requests a minute.
Amaros system uptime and running AI models
Retina clinics in the network market share
Pharma Data bases and 6 Languages supported
The backbone for ophthalmology
API requests per day, 1,200 requests a minute.
Amaros system uptime and running AI models
Retina clinics in the network market share
Pharma Data bases and 6 Languages supported
Unlocking potential strategies for growth
Inform
Current retinal therapeutic decisions to drive future therapeutic areas.
Accelerate
Drug development and build real-world comparator arms.
Inspire
New ways of thinking about how trials are designed.
Unlocking potential strategies for growth
Inform
Current retinal therapeutic decisions to drive future therapeutic areas.
Accelerate
Drug development and build real-world comparator arms.
Inspire
New ways of thinking about how trials are designed.
Unlocking potential strategies for growth
Inform
Current retinal therapeutic decisions to drive future therapeutic areas.
Accelerate
Drug development and build real-world comparator arms.
Inspire
New ways of thinking about how trials are designed.
What customers are saying
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
What customers are saying
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
What customers are saying
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
"The AmarosAI platform can significantly improve clinical study enrollment efficiency. The software has the potential to make studies more successful in meeting endpoints while being much more time and cost effective."
Neil Friedman, MD
Adjunct Clinical Professor of Ophthalmology, Stanford University School of Medicine
"My practice is involved in a variety of studies in ocular surface diseases. We see a lot of potential in a clinical study enrollment software that can help us take the labor out of identifying patients who might meet the enrollment criteria, as this is currently a manual process. By having a technology perform this task, we can focus our personnel efforts on preparing for and executing the studies at a high quality level."
Paul Karpecki, OD
Associate Professor, University of Pikeville, Kentucky College of Optometry
"I am enthusiastic about novel technology that utilizes artificial intelligence and machine learning to make clinical trial enrollment more efficient and successful. The time is right for this technology, as the costs for clinical trials continue to increase and clinical sites are seeking to improve efficiency and decrease study cost and labor required. The Amaros AI-based software is just the ideal technology that can achieve this goal."
T.Y. Alvin Liu, MD
Director, John Hopkins Wilmer Precision Ophthalmology Center of Excellence
Blog posts
Blog posts
Blog posts
Advance ophthalmology with our innovative solutions.
Empowering providers to deliver exceptional eye care. Transform patient outcomes with next-level technology.
Schedule a Demo
Advance ophthalmology with our innovative solutions.
Empowering providers to deliver exceptional eye care. Transform patient outcomes with next-level technology.
Schedule a Demo
Advance ophthalmology with our innovative solutions.
Empowering providers to deliver exceptional eye care. Transform patient outcomes with next-level technology.
Schedule a Demo
The Ophthalmic Answer Engine™
© 2024 Amaros, Inc. All rights reserved.
The Ophthalmic Answer Engine™
© 2024 Amaros, Inc. All rights reserved.
The Ophthalmic Answer Engine™
© 2024 Amaros, Inc. All rights reserved.